1. BROADEST PORTFOLIO WITH LEADING SCIENCE AND INNOVATION
Galderma has one of the broadest portfolios of clinically-proven flagship, synergistic brands in dermatology, which include Dysport/Azzalure and Alluzience (together the number two global neuromodulators franchise), Restylane (the number two global filler) and Sculptra (the number one global biostimulator) in Injectable Aesthetics; Cetaphil (the sensitive skincare brand recommended by nine out of ten U.S. dermatologists) and Alastin (the number one preferred peri-procedure skincare brand in the U.S.) in Dermatological Skincare; and the number one portfolio of leading brands across acne, rosacea and actinic keratosis in Therapeutic Dermatology.
To drive long-term sustainable growth, Galderma leverages its leading science and innovation capabilities. The Company has successfully strengthened its scientific differentiation as well as advanced its pipeline across product categories, including two clinically-derisked biologics with blockbuster potential: nemolizumab, a first-in-class biologic with a differentiated profile in the attractive prurigo nodularis (“PN”) and atopic dermatitis (“AD”) markets in Therapeutic Dermatology, and relabotulinumtoxinA (QM-1114), a next-generation liquid neuromodulator in Injectable Aesthetics.
2. GLOBAL SCALE WITH OMNI-CHANNEL EXECUTION EXCELLENCE
With presence in over 90 countries, Galderma is strategically positioned in attractive and consumer-driven market segments of dermatology, underpinned by high growth and resilient fundamentals. With its top seven markets driving more than 70% of net sales, Galderma’s global commercial presence has headroom for growth, especially through continued penetration in fast-growing geographies leveraging its synergistic flagship brands.
Galderma’s global reach is deepened and enhanced through omni-channel execution, including a specialized salesforce of over 1,900 employees engaging with over 110,000 healthcare professionals, a network covering over 270,000 retailers, retail stores and pharmacies, and activation through social media engagement with top campaigns reaching about 100 million impressions.
3. MARKET-LEADING EDUCATION AND SERVICES
Galderma has differentiated value-adding platforms, including market-leading education, scientific engagement and service offerings, which drive penetration and increase loyalty across Galderma’s portfolio.
With dermatology-focused healthcare professionals at the center of Galderma’s integrated dermatology strategy, Galderma showcases its commitment by training and engaging with over 240,000 healthcare professionals per year. This includes hosting over 11,000 events annually through the Galderma Aesthetics Injector Network (GAIN), a leading provider of medical education to aesthetic practices globally, as well as having leading presence at dermatology congresses globally. Other examples of value-adding offerings include ASPIRE, Galderma’s loyalty program in the U.S. for consumers and healthcare professionals, or tech-enabled solutions, such as FACE by Galderma and Cetaphil’s AI Skin Analysis.
